HAIFA, Israel, Jan. 26, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that it intends, subject to market and other conditions, to offer its common stock and warrants to purchase its common stock in a registered public offering pursuant to its existing shelf registration statement under the Securities Act of 1933, as amended. Pluristem also intends to grant the underwriters of the offering an option to purchase additional shares of common stock and warrants to cover over-allotments, if any. Pluristem plans to use the proceeds from the offering to conduct clinical trials, research and product development activities and for general corporate purposes, including general working capital purposes. Oppenheimer & Co. Inc. is acting as the sole bookrunner and Needham & Company, LLC is acting as co-lead manager for the offering.
Pluristem Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.